Guwahati Mail

Scleroderma Treatment Market Size, Epidemiology, Leading Companies, Drugs And Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Scleroderma Treatment Market Size, Epidemiology, Leading Companies, Drugs And Competitive Analysis By DelveInsight

October 28
05:54 2021
Scleroderma Treatment Market Size, Epidemiology, Leading Companies, Drugs And Competitive Analysis By DelveInsight
Scleroderma Treatment Market

DelveInsight’s ” Scleroderma Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Scleroderma, historical and forecasted epidemiology as well as the Scleroderma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some facts of Scleroderma Market:

  • In the United States, the prevalence of scleroderma is 240 per million and an annual incidence of 19 per million.
  • In Europe, the prevalence of scleroderma is estimated to be between 10 and 150 per million people, while the annual incidence has been reported to be between 3 and 28 per million people.
  • Women are four times more prone to develop systemic scleroderma than men.


Scope of Scleroderma Market Reports:

  • The report covers the descriptive overview of Scleroderma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Scleroderma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Scleroderma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Scleroderma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Scleroderma market


Request for Free Sample Report:


Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. It causes tissue throughout the body, including the lungs and other organs, to thicken and scar. SSc-ILD is a progressive lung disease in which lung function declines over time, and it can be debilitating and life-threatening. ILD is the leading cause of death among people with scleroderma, typically resulting from a loss of pulmonary function that occurs when the lungs cannot supply enough oxygen to the heart. Scleroderma is majorly of two types: localized scleroderma and systemic sclerosis (SSc).


Some of Scleroderma Companies:

  • Boehringer Ingelheim International GmbH
  • Corbus Pharmaceuticals Holdings, Inc.
  • Bayer AG
  • Gilead Sciences, Inc.
  • Allergan, Inc.
  • Pfizer, Inc.
  • Sanofi
  • GlaxoSmithKline plc
  • Cumberland Pharmaceuticals, Inc.
  • Actelion Pharmaceuticals, Inc.
  • And Many Others


Request for Free Sample Report:


Table of Contents:

  1. Key Insights
  2. Executive Summary of Scleroderma
  3. Competitive Intelligence Analysis for Scleroderma
  4. Scleroderma: Market Overview at a Glance
  5. Scleroderma: Disease Background and Overview
  6. Patient Journey
  7. Scleroderma Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Scleroderma Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Scleroderma: Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview of Scleroderma
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

DelveInsght’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States